Zobrazeno 1 - 9
of 9
pro vyhledávání: '"O'Sullivan, J."'
Autor:
Corcoran, R. M., MacDonagh, P., O'Connell, F., Morrissey, M. E., Dunne, M. R., Argue, R., O'Sullivan, J., Kevans, D.
Publikováno v:
Digestive Diseases & Sciences; Dec2022, Vol. 67 Issue 12, p5540-5550, 11p
Autor:
O'Farrell, N. J., Feighery, R., Picardo, S. L., Lynam-Lennon, N., Biniecka, M., McGarrigle, S. A., Phelan, J. J., MacCarthy, F., O'Toole, D., Fox, E. J., Ravi, N., Reynolds, J. V., O'Sullivan, J.
Publikováno v:
BMC Cancer; 7/19/2016, Vol. 16, p1-9, 9p, 5 Graphs
Autor:
Picardo, S. L., O'Brien, M. P., Feighery, R., O'Toole, D., Ravi, N., O'Farrell, N. J., O'Sullivan, J. N., Reynolds, J. V.
Publikováno v:
Diseases of the Esophagus; Feb2015, Vol. 28 Issue 2, p121-126, 6p
Publikováno v:
Prostate Cancer & Prostatic Diseases; 2009, Vol. 12 Issue 4, p325-332, 8p, 1 Diagram, 2 Charts
Autor:
O'Sullivan, J M, McCready, V R, Flux, G, Norman, A R, Buffa, F M, Chittenden, S, Guy, M, Pomeroy, K, Cook, G, Gadd, J, Treleaven, J, Al-Deen, A, Horwich, A, Huddart, R A, Dearnaley, D P
Publikováno v:
British Journal of Cancer; 6/5/2002, Vol. 86 Issue 11, p1715-1720, 6p
Autor:
Phelan, J.J.1, Feighery, R.1, Eldin, O.S.2, Meachair, S.Ó.3, Cannon, A.1, Byrne, R.1, MacCarthy, F.4, O'Toole, D.4, Reynolds, J.V.1, O'Sullivan, J.1 osullij4@tcd.ie, O'Toole, D5 (AUTHOR), O'Sullivan, J6 (AUTHOR)
Publikováno v:
Cancer Letters. Feb2016, Vol. 371 Issue 2, p334-346. 13p.
Autor:
Murphy, R. (AUTHOR), Payan, N. (AUTHOR), Osman, S. (AUTHOR), Prise, K. (AUTHOR), Hounsell, A. (AUTHOR), O'Sullivan, J. (AUTHOR), McGarry, C. (AUTHOR), Jain, S. (AUTHOR)
Publikováno v:
Radiotherapy & Oncology. 2022 Supplement 1, Vol. 170, pS1572-S1574. 3p.
Autor:
Cécile Bénézech, Carolynn Cairns, Oliver Teenan, Katie Connor, James O’sullivan, Angela Salzano, David A. Ferenbach, Kevin Stewart, Eoin O'Sullivan, Neil C. Henderson, Peng Ding, Riinu Pius, Jeremy Hughes, Tamir Chandra, Laura Denby, Duncan Humphries, Prakash Ramachandran, Bryan R. Conway, Daniel J. Simpson
Publikováno v:
J Am Soc Nephrol
Conway, B R, O Sullivan, E, Cairns, C, O'Sullivan, J, Simpson, D, Salzano, A, Connor, K, Ding, P, Humphries, D, Stewart, K, Teenan, O, Pius, R, Henderson, N C, Benezech, C, Ramachandran, P, Ferenbach, D A, Hughes, J, Chandra, T & Denby, L 2020, ' Kidney single-cell atlas reveals myeloid heterogeneity in progression and regression of kidney disease ', Journal of the American Society of Nephrology, vol. 31, no. 12, pp. 2833–2854 . https://doi.org/10.1681/ASN.2020060806
Conway, B R, O Sullivan, E, Cairns, C, O'Sullivan, J, Simpson, D, Salzano, A, Connor, K, Ding, P, Humphries, D, Stewart, K, Teenan, O, Pius, R, Henderson, N C, Benezech, C, Ramachandran, P, Ferenbach, D A, Hughes, J, Chandra, T & Denby, L 2020, ' Kidney single-cell atlas reveals myeloid heterogeneity in progression and regression of kidney disease ', Journal of the American Society of Nephrology, vol. 31, no. 12, pp. 2833–2854 . https://doi.org/10.1681/ASN.2020060806
Background Little is known about the roles of myeloid cell subsets in kidney injury and in the limited ability of the organ to repair itself. Characterizing these cells based only on surface markers using flow cytometry might not provide a full pheno
Autor:
Cook, Audrey, Beesley, Sharon, O'Sullivan, Joe M, Birtle, Alison J, Thalmann, George, Graham, John D, Spears, Melissa R, Brock, Susannah, Srinivasan, Rajaguru, Protheroe, Andrew, Sydes, Matthew R, Laing, Robert, Cross, William, Matheson, David, Tsang, David, Parmar, Mahesh K B, Sundar, Santhanam, McKinna, Fiona, Parikh, Omi, Chowdhury, Simon, Robinson, Angus J, De Bono, Johann, Elliott, Tony, Mason, Malcolm D, Parker, Christopher C, Alzouebi, Mymoona, Gibbs, Stephanie, Dearnaley, David P, Millman, Robin, Russell, J Martin, Tolan, Shaun, Chakraborti, Prabir, Cathomas, Richard, Srihari, Narayanan, Clarke, Noel W, Peedell, Clive, James, Nicholas D, Staffurth, John, Gale, Joanna, Hetherington, John, Amos, Claire, Attard, Gerhardt, Hughes, Robert, Jones, Rob J, Ritchie, Alastair W S, McLaren, Duncan B, Wagstaff, John
Publikováno v:
James, N D, Sydes, M R, Clarke, N W, Mason, M D, Dearnaley, D P, Spears, M R, Ritchie, A W S, Parker, C C, Russell, J M, Attard, G, de Bono, J, Cross, W, Jones, R J, Thalmann, G, Amos, C, Matheson, D, Millman, R, Alzouebi, M, Beesley, S, Birtle, A J, Brock, S, Cathomas, R, Chakraborti, P, Chowdhury, S, Cook, A, Elliott, T, Gale, J, Gibbs, S, Graham, J D, Hetherington, J, Hughes, R, Laing, R, McKinna, F, McLaren, D B, O'Sullivan, J M, Parikh, O, Peedell, C, Protheroe, A, Robinson, A J, Srihari, N, Srinivasan, R, Staffurth, J, Sundar, S, Tolan, S, Tsang, D, Wagstaff, J, Parmar, M K B & STAMPEDE investigators 2016, ' Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial ', Lancet, vol. 387, no. 10024, pp. 1163–1177 . https://doi.org/10.1016/S0140-6736(15)01037-5
Lancet (London, England), vol. 387, no. 10024, pp. 1163-1177
Lancet, vol. 387, no. 10024, pp. 1163-1177
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, Sharon; Birtle, Alison J; ... (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. Elsevier 10.1016/S0140-6736(15)01037-5
Lancet (London, England), vol. 387, no. 10024, pp. 1163-1177
Lancet, vol. 387, no. 10024, pp. 1163-1177
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, Sharon; Birtle, Alison J; ... (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. Elsevier 10.1016/S0140-6736(15)01037-5
BACKGROUND: Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced